Crinetics Pharmaceuticals Q3 revenue misses estimates

Crinetics Pharmaceuticals

06/11/2025 22:27

Overview

Crinetics Q3 revenue missed analyst expectations

Net loss for Q3 was $130.1 mln, compared to $76.8 mln last year

Outlook

Company anticipates cash runway into 2029

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to personnel costs and clinical activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$143,000
$637,200 (12 Analysts)
Q3 Net Income
-$130.09 mln
Q3 Basic EPS
-$1.38
Q3 Operating Expenses
$142.73 mln
Q3 Operating Income
-$142.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $83.00, about 48.8% above its November 5 closing price of $42.53

Press Release: ID:nGNXmyJrS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)